- Molecular NameRotigotine transdermal patch
- Synonymrotigotine transdermal patch
- Weight315.481
- Drugbank_IDDB05271
- ACS_NO92206-54-7
- Show 3D model
- LogP (experiment)4.03
- LogP (predicted, AB/LogP v2.0)4.52
- pkaN/A
- LogD (pH=7, predicted)2.91
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.75
- LogSw (predicted, AB/LogsW2.0)0.74
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds6
- TPSA51.71
- StatusFDA approved
- AdministrationTransdermal patch
- PharmacologyA non-ergoline dopamine agonist psychoactive drug and is indicated for the treatment of Parkinson's disease (PD).
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding92.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRotigotine is extensively metabolized by conjugation and N-dealkylation. After intravenous dosing the predominant metabolites in human plasma are sulfate conjugates of rotigotine, glucuronide conjugates of rotigotine, sulfate conjugates of the N-despropyl-rotigotine and conjugates of N-desthienyl -rotigotine. Multiple CYP isoenzymes, sulfotransferases and two UDP-glucuronosyltransferases catalyze the metabolism of rotigotine.
- Half life5~7 h
- ExcretionRenal (71%) and fecal (23%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A